Granted Patent B2

US 12,544,409 · App. 17/528,822 · Granted Feb 10, 2026

Inventors: Eduardo Marban (Santa Monica, CA); Mark Amin Aminzadeh (Los Angeles, CA)

Assignee: Cedars-Sinai Medical Center

A61K35/34A61K9/0019A61K31/713A61K38/1709A61P9/10A61P21/00C12N15/113C12N2310/141C12N2320/31C12N2320/32

Abstract

Claims (24)

1 . A method of reducing oxidative stress and inflammation in the heart of a subject with muscular dystrophy, comprising:

selecting a subject having muscular dystrophy who is in need of treatment;

obtaining a composition comprising cardiosphere-derived cells; and

intravenously administering the composition comprising cardiosphere-derived cells to the subject;

wherein composition comprising cardiosphere-derived cells comprises a therapeutic amount of cardiosphere-derived cells; and

wherein administration of the composition comprising cardiosphere-derived cells to the subject reverses NFκB activation or decreases inflammatory cell number in the heart of the subject.

2 . The method of claim 1 , wherein a dose of the composition comprising cardiosphere-derived cells comprises 1×10 7 to 1×10 9 cardiosphere-derived cells.

3 . The method of claim 1 , wherein a single dose is administered multiple times to the subject.

4 . The method of claim 3 , wherein the single dose of the composition comprising cardiosphere-derived cells comprises 1×10 5 to 1×10 9 cardiosphere-derived cells.

5 . The method of claim 1 , wherein said administering of said composition to the subject results in one or more of decreased fibrosis, decreased inflammation, increased mitochondrial function, or increased cardiomyogenesis.

6 . The method of claim 5 , wherein the decreased fibrosis comprises a reduction in collagen accumulation.

7 . The method of claim 5 , wherein the decreased inflammation comprises an increase in cytoplasmic nuclear factor (erythroid-derived 2)-like 2 (Nrf2), reduction in fatty acid peroxidation end products, reduced numbers of inflammatory cells, and/or upregulated expression of antioxidants.

8 . The method of claim 7 , wherein the antioxidants comprise heme oxygenase-1 (HO-1), catalase, superoxide dismutase-2 (SOD-2), or glutamate-cystein ligase catalytic (GCLC) subunit.

9 . The method of claim 5 , wherein the increased mitochondrial function comprises increased mitochondrial ultrastructure or increased mitochondrial biogenesis.

10 . The method of claim 1 , wherein the muscular dystrophy is Duchenne muscular dystrophy.

11 . A method of reducing oxidative stress and inflammation in the heart of a subject with Duchenne muscular dystrophy, comprising:

selecting a subject with Duchenne muscular dystrophy in need of treatment; and

intravenously administering a composition comprising cardiosphere-derived cells to the subject, thereby treating the subject;

wherein composition comprises a therapeutic amount of cardiosphere-derived cells.

12 . The method of claim 11 , wherein administering the composition comprises providing one or more doses of about 1×10 5 to about 1×10 8 or more cardiosphere-derived cells to the subject.

13 . The method of claim 11 , wherein said administering of said composition to the subject results in one or more of decreased fibrosis, decreased inflammation, increased mitochondrial function, or increased cardiomyogenesis.

14 . The method of claim 13 , wherein the decreased fibrosis comprises a reduction in collagen accumulation.

15 . The method of claim 13 , wherein the decreased inflammation comprises an increase in cytoplasmic nuclear factor (erythroid-derived 2)-like 2 (Nrf2), reduction in fatty acid peroxidation end products, reduced numbers of inflammatory cells, or upregulated expression of antioxidants.

16 . The method of claim 15 , wherein the antioxidants comprise heme oxygenase-1 (HO-1), catalase, superoxide dismutase-2 (SOD-2), and/or glutamate-cystein ligase catalytic (GCLC) subunit.

Assignments (2)

Continuity (3)

References Cited (400)